Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System (Inventa)

Bayer

Status: Completed

Conditions: Pulmonary Arterial Hypertension

Treatments: Other: Iloprost (Ventavis inhaled, BAYQ6256)

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT01468545

BAY-ILO-2010-01 (Other Identifier)

15554

Details and patient eligibility

About

Ventavis it's a treatment for pulmonary hypertension, administered by an inhaler called I-Neb.

In these patients, the non compliance of the treatment becomes its ineffective and increases the complications and mortality of the disease.

It is therefore important to know which the adherence of patients to their treatment is and try to promote it.

One possibility to reach a good level of adherence is the patient education regarding the drug administration and also to comply as better is possible the recommendations of the physician.

For this reason, the objective of our study is to demonstrate improvement in the level of treatment compliance when they follow a strategy of continuing education, assessed by the device and software called Insight.

The only special procedure to participate in the study then is that patients involved could receive more training than usual.

Investigators expect involving in this study around 50 patients in treatment with Ventavis and diagnosed of Pulmonary Arterial Hypertension in 10-12 hospitals throughout Spain.

The patients who participated in the study will be followed for 12 months from inclusion in the study and will perform around 5 visits in total.

Enrollment: 38 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female patients > 18 years of age.
• Patients in New York Heart Association (NYHA) functional class II-IV pulmonary hypertension who are treated with Ventavis at least three months before and who use -neb ® AAD ® system.
• Patients who accepted participation in the study and sign informed consent.
• Patients with ability to understand and follow the instructions and are able to participate for the duration of the study.

Exclusion criteria

• Patients with severe cognitive impairment.
• Geographically unstable patients who can not be followed during the 12 month study.
• Patients who have a life expectancy of at least 12 months.
• Patients who are participating in another study at the time of inclusion. .

Trial design

38 participants in 2 patient groups

Group 1

Treatment:

Other: Iloprost (Ventavis inhaled, BAYQ6256)

Other: Iloprost (Ventavis inhaled, BAYQ6256)

Group 2

Treatment:

Other: Iloprost (Ventavis inhaled, BAYQ6256)

Other: Iloprost (Ventavis inhaled, BAYQ6256)